[Dilip Davda] This pharma/healthcare segment company has marked wild fluctuations in its bottom lines for the reported periods. Based on FY23 annualized earnings, the issue appears exorbitantly priced. It is operating in a highly competitive and fragmented segment. SPL’s debt level is also higher and raises concerns. There is no harm in skipping this pricey bet. Read detail review...

Sotac Pharmaceuticals IPO Review by Members

Sotac Pharmaceuticals IPO Reviews, analysis and views by popular members. Read Sotac Pharmaceuticals Ltd. IPO reviews by retail investors to find recommended ipo to buy.

Sotac Pharmaceuticals IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	0	0	0	0
%	0.00	0.00	0.00	0.00

Member	Review
No recommendation found. Be the first to post the recommendation.

Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

Sotac Pharmaceuticals IPO Review & Recommendations

Sotac Pharmaceuticals IPO Review Summary from brokers and analysts

Sotac Pharmaceuticals IPO Review by Dilip Davda (Avoid)

Sotac Pharmaceuticals IPO Review by Members

Sotac Pharmaceuticals IPO Review Summary by Members

Read more about Sotac Pharmaceuticals IPO